Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2012 1
2013 3
2014 5
2015 4
2016 1
2017 3
2018 1
2019 6
2020 8
2021 2
2022 9
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean houjin huang[Author] (21 results)?
Anti-Epstein-Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer.
Li T, Li F, Guo X, Hong C, Yu X, Wu B, Lian S, Song L, Tang J, Wen S, Gao K, Hao M, Cheng W, Su Y, Zhang S, Huang S, Fang M, Wang Y, Ng MH, Chen H, Luo W, Ge S, Zhang J, Xia N, Ji M. Li T, et al. Among authors: huang s. N Engl J Med. 2023 Aug 31;389(9):808-819. doi: 10.1056/NEJMoa2301496. N Engl J Med. 2023. PMID: 37646678
Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters.
Zhang L, Jiang Y, He J, Chen J, Qi R, Yuan L, Shao T, Zhao H, Chen C, Chen Y, Wang X, Lei X, Gao Q, Zhuang C, Zhou M, Ma J, Liu W, Yang M, Fu R, Wu Y, Chen F, Xiong H, Nie M, Chen Y, Wu K, Fang M, Wang Y, Zheng Z, Huang S, Ge S, Cheng SC, Zhu H, Cheng T, Yuan Q, Wu T, Zhang J, Chen Y, Zhang T, Li C, Qi H, Guan Y, Xia N. Zhang L, et al. Among authors: huang s. Nat Commun. 2023 Jul 11;14(1):4117. doi: 10.1038/s41467-023-39560-9. Nat Commun. 2023. PMID: 37433761 Free PMC article.
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.
Zhao FH, Wu T, Hu YM, Wei LH, Li MQ, Huang WJ, Chen W, Huang SJ, Pan QJ, Zhang X, Hong Y, Zhao C, Li Q, Chu K, Jiang YF, Li MZ, Tang J, Li CH, Guo DP, Ke LD, Wu X, Yao XM, Nie JH, Lin BZ, Zhao YQ, Guo M, Zhao J, Zheng FZ, Xu XQ, Su YY, Zhang QF, Sun G, Zhu FC, Li SW, Li YM, Pan HR, Zhang J, Qiao YL, Xia NS. Zhao FH, et al. Lancet Infect Dis. 2022 Dec;22(12):1756-1768. doi: 10.1016/S1473-3099(22)00435-2. Epub 2022 Aug 26. Lancet Infect Dis. 2022. PMID: 36037823 Clinical Trial.
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial.
Zhu FC, Zhong GH, Huang WJ, Chu K, Zhang L, Bi ZF, Zhu KX, Chen Q, Zheng TQ, Zhang ML, Liu S, Xu JB, Pan HX, Sun G, Zheng FZ, Zhang QF, Yi XM, Zhuang SJ, Huang SJ, Pan HR, Su YY, Wu T, Zhang J, Xia NS. Zhu FC, et al. Lancet Infect Dis. 2023 Nov;23(11):1313-1322. doi: 10.1016/S1473-3099(23)00275-X. Epub 2023 Jul 17. Lancet Infect Dis. 2023. PMID: 37475116 Clinical Trial.
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Zhu F, Zhuang C, Chu K, Zhang L, Zhao H, Huang S, Su Y, Lin H, Yang C, Jiang H, Zang X, Liu D, Pan H, Hu Y, Liu X, Chen Q, Song Q, Quan J, Huang Z, Zhong G, Chen J, Han J, Sun H, Cui L, Li J, Chen Y, Zhang T, Ye X, Li C, Wu T, Zhang J, Xia NS. Zhu F, et al. Among authors: huang s. Lancet Respir Med. 2022 Aug;10(8):749-760. doi: 10.1016/S2213-2600(22)00131-X. Epub 2022 May 26. Lancet Respir Med. 2022. PMID: 35644168 Free PMC article. Clinical Trial.
Protective immunity against HEV.
Huang SJ, Liu XH, Zhang J, Ng MH. Huang SJ, et al. Curr Opin Virol. 2014 Apr;5:1-6. doi: 10.1016/j.coviro.2013.10.003. Epub 2013 Nov 14. Curr Opin Virol. 2014. PMID: 24835679 Review.
Safety of hepatitis E vaccination for pregnancy: a post-hoc analysis of a randomized, double-blind, controlled phase 3 clinical trial.
Zhong G, Zhuang C, Hu X, Chen Q, Bi Z, Jia X, Peng S, Li Y, Huang Y, Zhang Q, Hong Y, Qiao Y, Su Y, Pan H, Wu T, Wei L, Huang S, Zhang J, Xia N. Zhong G, et al. Among authors: huang s. Emerg Microbes Infect. 2023 Dec;12(1):2185456. doi: 10.1080/22221751.2023.2185456. Emerg Microbes Infect. 2023. PMID: 36877135 Free PMC article. Clinical Trial.
Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Huang S, Zhang X, Su Y, Zhuang C, Tang Z, Huang X, Chen Q, Zhu K, Hu X, Ying D, Liu X, Jiang H, Zang X, Wang Z, Yang C, Liu D, Wang Y, Tang Q, Shen W, Cao H, Pan H, Ge S, Huang Y, Wu T, Zheng Z, Zhu F, Zhang J, Xia N. Huang S, et al. Lancet. 2024 Mar 2;403(10429):813-823. doi: 10.1016/S0140-6736(23)02234-1. Epub 2024 Feb 19. Lancet. 2024. PMID: 38387470 Clinical Trial.
52 results